An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Sponsor: AstraZeneca
Terminated
An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility
Other terminated trials from AstraZeneca
Other Alzheimer´s Disease trials with similar outcome
This PHASE2/PHASE3 trial investigates Alzheimer´s Disease and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 22 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 17 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2020 — Nov 2020 [monthly]
Terminated PHASE2_PHASE3
-
Sep 2019 — Jan 2020 [monthly]
Terminated PHASE2_PHASE3
-
Nov 2018 — Sep 2019 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Active Not Recruiting → Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Allentown, United States , Ancona, Italy , Anderson, United States , Asahikawa, Japan , Atlanta, United States , Austin, United States , Barcelona, Spain , Bayamón, Puerto Rico , Bennington, United States and 187 more locations